<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728959</url>
  </required_header>
  <id_info>
    <org_study_id>KS-4-HypoPT</org_study_id>
    <nct_id>NCT03728959</nct_id>
  </id_info>
  <brief_title>Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.</brief_title>
  <acronym>KS-4-HypoPT</acronym>
  <official_title>Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoparathyroidism (hypoPT) is characterized by low levels of PTH.

      In this study we will test the effects of a liquid meal on the bone remodeling in
      participants with hypoparathyroidism. Furthermore, we will test the effects of the gut
      hormones GIP and GLP-2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Actual">April 12, 2019</completion_date>
  <primary_completion_date type="Actual">April 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of C-terminal telopeptide (CTX)</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Marker of bone resorption, measured in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal propeptide of type 1 procollagen (P1NP)</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Marker of bone formation, concentration measured in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>PTH concentration measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Gut hormone, concentration measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-2 (GLP-2)</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Gut hormone, concentration measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1)</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Gut hormone, concentration measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Glucose concentration measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Insulin concentration measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>C-peptide concentration measured in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Blood pressure (systolic and diastolic) measured before blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>-10 to 240 minutes</time_frame>
    <description>Heart rate measured before blood sampling</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Liquid meal (Nutridrink)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid meal (Nutridrink)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose-dependent insulinotropic polypeptide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-like peptide-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid meal (Nutridrink)</intervention_name>
    <description>Liquid meal ingested over 1 minute.</description>
    <arm_group_label>Liquid meal (Nutridrink)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>Subcutaneous injected GIP</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>Subcutaneous injected GLP-2</description>
    <arm_group_label>GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Subcutaneous injected Placebo (saline)</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 76

          -  Hypoparathyroidism

        Exclusion Criteria:

          -  Diabetes

          -  Disease in the gastrointestinal tract

          -  Antiosteoporotic drug

          -  Long term steroid treatment (within the last 12 months)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Rosenkilde, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsa Skov-Jeppesen</investigator_full_name>
    <investigator_title>principal investigator. Cand.pharm., ph.d. student</investigator_title>
  </responsible_party>
  <keyword>hypoparathyroidism</keyword>
  <keyword>Glucose-dependent insulinotropic polypeptide (GIP)</keyword>
  <keyword>Glucagon-like peptide-2 (GLP-2)</keyword>
  <keyword>Bone remodeling</keyword>
  <keyword>Bone resorption</keyword>
  <keyword>Bone formation</keyword>
  <keyword>C-terminal telopeptide (CTX)</keyword>
  <keyword>N-terminal propeptide of type 1 procollagen (P1NP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

